Business Context and Reporting Period
This Form 8-K Current Report was filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on December 18, 2012. The filing reports the completion of a private equity offering and the implementation of a reverse stock split effective as of 9:00 a.m. EST on December 18, 2012.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company completed the sale of 9,166,665 shares of common stock and warrants to purchase an additional 6,416,665 shares for an aggregate offering price of $27.5 million.
- Transaction Costs: Stifel, Nicolaus & Company, Inc. received a placement fee of 6% ($1.65 million). Trout Group received an advisory fee of 25 basis points ($68,750).
- Warrant Terms: Warrants are exercisable at $3.12 per share and expire on December 17, 2017.
- Share Count Impact: Following the reverse stock split and the new issuance, the number of issued and outstanding shares decreased from approximately 27.2 million to approximately 13.7 million.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, or debt data.
Material Changes Versus Prior Period
- Reverse Stock Split: A 1-for-6 reverse stock split was executed, reducing the total share count and adjusting the exercise price and share counts of all outstanding options and warrants proportionately.
- Corporate Governance: The Board of Directors was expanded from six to seven members. Governance agreements were entered into with Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P., granting them rights to propose board candidates and influence board leadership roles.
- Bylaw Amendments: Bylaws were amended to clarify indemnification obligations, establishing the Company's indemnification as primary and stockholder indemnification as secondary.
Outlook, Risks, and Unusual Items
- Management Commentary: The filing focuses on the mechanics of the capital raise and corporate restructuring rather than operational outlook or product pipeline updates.
- Unusual Items: The transaction involved a significant dilution event (issuance of new shares) immediately followed by a consolidation of shares (reverse split) to adjust the capital structure.
- Risks: The filing notes that fractional shares resulting from the reverse split were sold by the transfer agent, with proceeds distributed to affected holders.
Investor Verification Checklist
- Verify the post-split share count of approximately 13.7 million shares.
- Confirm the new CUSIP number for the common stock: 55279B 202.
- Review the specific terms of the Governance Agreements with Vivo and New Leaf regarding board composition.
- Check the adjusted exercise prices for any pre-existing options or warrants held by the investor.
- Confirm the net proceeds received by the Company after deducting the $1.71875 million in total fees.